ストックスクリーナーアプリを入手
0.8188
0.87%
-0.0072
アフターアワーズ：
.82
0.0012
+0.15%
前日終値:
$0.826
開ける：
$0.83
24時間の取引高:
87,391
Relative Volume:
0.29
時価総額：
$62.92M
収益：
$9.53M
当期純損益:
$-44.61M
株価収益率:
-0.8998
EPS:
-0.91
ネットキャッシュフロー:
$-38.32M
1週間 パフォーマンス:
-1.52%
1か月 パフォーマンス:
-9.02%
6か月 パフォーマンス:
-40.67%
1年 パフォーマンス:
+20.59%
1日の値動き範囲:
$0.782
$0.83
1週間の範囲:
$0.76
$0.84
52週間の値動き範囲:
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
CUE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.8188 | 63.47M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.88 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.87 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.91 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
661.32 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.32 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-13 | 開始されました | Jefferies | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2022-11-21 | 開始されました | Piper Sandler | Overweight |
| 2022-01-13 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-03 | 開始されました | Craig Hallum | Buy |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-04-09 | 開始されました | Stifel | Buy |
| 2020-01-28 | 開始されました | BTIG Research | Buy |
| 2020-01-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Cue Biopharma Inc (CUE) 最新ニュース
Cue Biopharma’s Q2 2025: Strategic Advances and Financial Highlights - TipRanks
Cue Biopharma Inc. stock daily chart insightsSwing Trade & Safe Investment Capital Preservation Plans - Newser
Regression analysis insights on Cue Biopharma Inc. performanceLong Setup & Real-Time Buy Signal Notifications - Newser
Published on: 2025-08-17 18:02:43 - Newser
Intraday pattern recognizer results for Cue Biopharma Inc.Oil Prices & Verified Technical Signals - Newser
Evaluating Cue Biopharma Inc. with trendline analysis2025 AllTime Highs & Daily Chart Pattern Signals - Newser
Is Cue Biopharma Inc. trading at a discount2025 Support & Resistance & Target Return Focused Stock Picks - thegnnews.com
Why Cue Biopharma Inc. stock attracts strong analyst attention2025 Macro Impact & Low Drawdown Momentum Ideas - Newser
How to read the order book for Cue Biopharma Inc.Risk Management & Real-Time Buy Signal Alerts - Newser
What makes Cue Biopharma Inc. stock price move sharplyIPO Watch & Free Fast Entry Momentum Trade Alerts - Newser
How to recover losses in Cue Biopharma Inc. stockShare Buyback & Daily Oversold Bounce Ideas - Newser
Will Cue Biopharma Inc. stock go up soon2025 Historical Comparison & Weekly Top Gainers Trade List - Newser
News impact scoring models applied to Cue Biopharma Inc.July 2025 Intraday Action & Daily Stock Trend Reports - Newser
Should you avoid Cue Biopharma Inc. stock right nowFed Meeting & Low Risk High Reward Trade Ideas - thegnnews.com
Using AI based signals to follow Cue Biopharma Inc.Take Profit & Real-Time Chart Breakout Alerts - Newser
Why Cue Biopharma Inc. stock is on top investor watchlistsJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - Newser
How sentiment analysis helps forecast Cue Biopharma Inc.Market Activity Report & Daily Profit Maximizing Trade Tips - Newser
Will Cue Biopharma Inc. stock benefit from interest rate changesJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-08-16 02:15:50 - Newser
Is Cue Biopharma Inc. forming a bottoming baseEarnings Summary Report & AI Driven Stock Movement Reports - Newser
Order flow analysis tools used on Cue Biopharma Inc.2025 Market Outlook & Verified Short-Term Trading Plans - Newser
Intrinsic Value of Cue Biopharma Inc. Stock: Is It Undervalued or OvervaluedWeekly Profit Report & Low Drawdown Investment Ideas - Newser
How Cue Biopharma Inc. stock performs during market volatilityDip Buying & Stepwise Trade Execution Plans - Newser
Cue Biopharma Inc. Building a Base Near SupportStop Loss & Entry Point Strategy Guides - sundaytimes.kr
What technical models suggest about Cue Biopharma Inc.’s comeback - Newser
Cue Biopharma Reports Q2 2025 Earnings: Collaboration Revenue Exceeds Estimate, Net Loss Narrows - AInvest
Cue Biopharma's Q2 2025 Earnings Beat and Revenue Growth: A Glimpse of Sustainable Turnaround Potential? - AInvest
Cue Biopharma Announces Initiation of Investigator Sponsored Tri - GuruFocus
Cue Biopharma announces initiation of investigator sponsored trial of CUE-102 - TipRanks
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme - The Manila Times
Dana-Farber Launches Trial of New Immunotherapy Drug for Aggressive Brain Cancer - Stock Titan
Cue Biopharma Inc. Facing Inflection Point in Trend Analysis2025 Buyback Activity & Weekly Top Performers Watchlists - sundaytimes.kr
Cue Biopharma Inc. stock daily chart insights [July 2025 Recap]Consistent Profit Trade Alerts - Newser
Cue Biopharma 2025 Q2 Earnings Narrowed Losses with Modest Revenue Growth - AInvest
Can machine learning forecast Cue Biopharma Inc. recoveryFree Risk Controlled Picks With Real Returns - Newser
Advanced analytics toolkit walkthrough for Cue Biopharma Inc.Trade Exit Summary & AI Based Buy and Sell Signals - Newser
Short interest data insights for Cue Biopharma Inc.Free Consistent Gain Investment Strategies - Newser
Cue Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Cue Biopharma Inc (CUE) 財務データ
収益
当期純利益
現金流量
EPS
1.18%
大文字化:
|
ボリューム (24 時間):